Zacks Focus Growth ETF (GROZ)
Live price chart, market sentiment, and community perspectives for Zacks Focus Growth ETF (CBOE: GROZ).
Live price chart, market sentiment, and community perspectives for Zacks Focus Growth ETF (CBOE: GROZ).
On our desk, we are looking closely at the liquidity profile of GROZ. With an average daily dollar volume sitting around $327,120, a standard allocation of $20,000 eats up roughly 6% of a single day's volume. That introduces massive market-impact costs on both entry and exit, making it completely unviable for large capital deployers who require clean execution without moving the order book.
Watching the moving averages, GROZ is currently struggling below its key thresholds, with the price at $27.84 lagging behind the MA20 ($28.02), MA50 ($28.81), and MA200 ($28.72). While the daily RSI of roughly 46 hints at mild oversold conditions, the severe -38% intra-year peak-to-trough drawdown proves that this vehicle can shed value rapidly during growth corrections.
Evaluating the underlying fundamentals, the fund's projected long-term earnings growth of 17.16% outpaces the category average of 14.52%. Combined with a portfolio turnover rate of 50%—which is notably lower than the category average of 73%—the fundamental stock selection shows some merit, provided investors can stomach the frictional costs of a 0.55% expense ratio and wide spreads.
From a portfolio construction standpoint, the fund's 42-stock concentrated focus is a double-edged sword. With the top four names accounting for roughly 34% of total assets, any top-heavy softening will immediately pressure the entire wrapper. Analysts must weigh this lack of diversification against the appeal of its lower-than-average forward P/E of 22.83x.
On our options and trading desk, the nearly 120 basis point bid-ask spreads are a major deterrent. Even if the trailing 1-year return looks robust around 24.06%, trading friction alone can easily claw back a massive portion of any short-term alpha generated by the underlying equity selections.
As a risk manager, I am hyper-aware of the macroeconomic sensitivity tied to GROZ's growth tilt. Rising-rate environments aggressively compress valuations for high-beta instruments, and with a beta ranging between 1.19 and 1.22, this ETF will heavily amplify category losses when broader financial conditions tighten.
Explore plasma cleansing, somatic organ swaps, and BCI.